AI-powered PET scans may predict prostate cancer aggressiveness before surgery

NCT ID NCT07655648

Completed Knowledge-focused Sponsor: Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special type of PET scan, using two different tracers, can help predict how aggressive a person's prostate cancer is before surgery. Researchers will use computer models to analyze the scan images and compare the results with standard biopsy and surgical findings. The goal is to see if this imaging method can better classify cancer risk and predict whether the cancer might come back after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gallium-68 labeled PSMA and RM26
What this could lead to: If successful, this approach could help doctors determine prostate cancer aggressiveness without invasive biopsy, guiding treatment decisions more accurately.
What could go wrong: This is a small, retrospective study at a single center. The model may not work as well in other hospitals or diverse patient groups, and it is not yet ready for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOCHEMICAL RECURRENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOCHEMICAL RECURRENCE GLEASON SCORE PET/CT PROSTATE CANCER RADIOMICS

Contacts and locations

Locations

Department of Nuclear Medicine, Xiangya Hospital, Central South University

Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.